Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Behavioural Brain Research

Volumn 235, Issue 2, 2012, Pages 263-272

  Matheus, Filipe C ^a   Aguiar, Aderbal S ^a   Castro, Adalberto A ^a   Villarinho, Jardel G ^b   Ferreira, Juliano ^b   Figueiredo, Cláudia P ^c   Walz, Roger ^a   Santos, Adair R S ^a   Tasca, Carla I ^a   Prediger, Rui D S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Aging mice; Agmatine; Intranasal; Non motor symptoms; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AGMATINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; EMOTIONAL DISORDER; FEMALE; LOCOMOTION; MOTOR DYSFUNCTION; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OLFACTORY NERVE DISEASE; PRIORITY JOURNAL; SHORT TERM MEMORY; SINGLE DRUG DOSE; SUBSTANTIA NIGRA PARS COMPACTA; SURVIVAL RATE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, INTRANASAL; AGMATINE; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RECOGNITION (PSYCHOLOGY); SOCIAL BEHAVIOR; SUBSTANTIA NIGRA; SURVIVAL ANALYSIS; TRITIUM; TYROSINE 3-MONOOXYGENASE;

EID: 84865553365     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.08.017     Document Type: Article

References (74)

1. Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurology 2009, 7:613-618.
2. Ambrosio S., Blesa R., Mintenig G.M., Palacios-Araus L., Mahy N., Gual A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat. Toxicology Letters 1988, 44:1-6.
3. Antzoulatos E., Jakowec M.W., Petzinger G.M., Wood R.I. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease. Pharmacology Biochemistry and Behavior 2010, 95:466-472.
4. Arndt M.A., Battaglia V., Parisi E., Lortie M.J., Isome M., Baskerville C., et al. The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. American Journal of Physiology - Cell Physiology 2009, 6:1411-1419.
5. Battaglia V., Grancara S., Satriano J., Saccoccio S., Agostinelli E., Toninello A. Agmatine prevents the Ca(2+)-dependent induction of permeability transition in rat brain mitochondria. Amino Acids 2010, 2:431-437.
6. Battaglia V., Rossi C.A., Colombatto S., Grillo M.A., Toninello A. Different behavior of agmatine in liver mitochondria: inducer of oxidative stress or scavenger of reactive oxygen species. Biochimica et Biophysica Acta 2007, 5:1147-1153.
7. Bergin D.H., Liu P. Agmatine protects against beta-amyloid25-35-induced memory impairments in the rat. Neuroscience 2010, 169:794-811.
8. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B., Gross C.E. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. European Journal of Neuroscience 2000, 12:2892-2900.
9. Bhutada P., Mundhada Y., Humane V., Rahigude A., Deshmukh P., Latad S., et al. Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012, 37:96-105.
10. Blandini F., Greenamyre J.T., Nappi G. The role of glutamate in the pathophysiology of Parkinson's disease. Functional Neurology 1996, 11:16-19.
11. Bosboom J.L., Stoffers D., Wolters E.Ch. Cognitive dysfunction and dementia in Parkinson's disease. Journal of Neural Transmission 2004, 111:1303-1315.
12. Castro A.A., Ghisoni K., Latini A., Quevedo J., Tasca C.I., Prediger R.D. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behavioural Brain Research 2012, 229:208-215.
13. Chaudhuri K.R., Healy D.G., Schapira A.H., National Institute for Clinical Excellence Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurology 2006, 5:235-245.
14. Cobos-Puc L.E., Villalón C.M., Ramírez-Rosas M.B., Sánchez-López A., Lozano-Cuenca J., Gómez-Díaz B., et al. Pharmacological characterization of the inhibition by moxonidine and agmatine on the cardioaccelerator sympathetic outflow in pithed rats. European Journal of Pharmacology 2009, 616:175-182.
15. Condello S., Calabrò E., Caccamo D., Currò M., Ferlazzo N., Satriano J., et al. Protective effects of agmatine in rotenone-induced damage of human SH-SY5Y neuroblastoma cells: Fourier transform infrared spectroscopy analysis in a model of Parkinson's disease. Amino Acids 2012, 42:775-781.
16. Condello S., Currò M., Ferlazzo N., Caccamo D., Satriano J., Ientile R. Agmatine effects on mitochondrial membrane potential and NF-(B activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. Journal of Neurochemistry 2011, 116:67-75.
17. Demehri S., Homayoun H., Honar H., Riazi K., Vafaie K., Roushanzamir F., et al. Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 2003, 4:534-542.
18. Di Monte D.A., Tokar I., Langston J.W. Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures. Toxicology and Applied Pharmacology 1999, 3:296-302.
19. Di Monte D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins. Lancet Neurology 2003, 2:531-538.
20. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., Muenter M.D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990, 40:763-766.
21. Dluzen D.E., Kefalas G. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Research 1996, 2:215-219.
22. Doty R.L. The olfactory vector hypothesis of neurodegenerative disease: is it viable. Annals of Neurology 2008, 1:7-15.
23. Emre M., Tsolaki M., Bonuccelli U., Destée A., Tolosa E., Kutzelnigg A., et al. 11018 Study investigators memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2010, 9:969-977.
24. Felicio L.S., Nelson J.F., Finch C.E. Longitudinal studies of estrous cyclicity in aging C57BL/6J mice: II. Cessation of cyclicity and the duration of persistent vaginal cornification. Biology of Reproduction 1984, 3:446-453.
25. Flierl M.A., Stahel P.F., Beauchamp K.M., Morgan S.J., Smith W.R., Shohami E. Mouse closed head injury model induced by a weight-drop device. Nature Protocols 2009, 9:1328-1337.
26. Freyaldenhoven T.E., Cadet J.L., Ali S.F. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent. Brain Research 1996, 735:232-238.
27. Freyaldenhoven T.E., Ali S.F., Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Research 1995, 688:161-170.
28. Gadotti V.M., Tibola D., Paszcuk A.F., Rodrigues A.L., Calixto J.B., Santos A.R. Contribution of spinal glutamatergic receptors to the antinociception caused by agmatine in mice. Brain Research 2006, 1093:116-122.
29. Galea E., Regunathan S., Eliopoulos V., Feinstein D.L., Reis D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochemical Journal 1998, 316:247-249.
30. Gilad G.M., Gilad V.H., Finberg J.P., Rabey J.M. Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochemical Research 2005, 7:713-719.
31. Gilad G.M., Salame K., Rabey J.M., Gilad V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sciences 1996, 58:41-46.
32. Gong Z.H., Li Y.F., Zhao N., Yang H.J., Su R.B., Luo Z.P., et al. Anxiolytic effect of agmatine in rats and mice. European Journal of Pharmacology 2006, 3:112-116.
33. Groenewegen H.J., Berendse H.W. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. Journal of Comparative Neurology 1990, 22:607-622.
34. Halaris A., Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 2007, 11:885-900.
35. Hazell A.S., Itzhak Y., Liu H., Norenberg M.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. Journal of Neurochemistry 1997, 5:2216-2219.
36. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
37. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
38. Ho Y.J., Ho S.C., Pawlak C.R., Yeh K.Y. Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia. Behavioural Brain Research 2011, 219:280-290.
39. Hsu K.S., Fu W.M., Lin-Shiau S.Y. Studies on the neuromuscular blocking action of MPTP in the mouse phrenic nerve-diaphragm. Neuropharmacology 1993, 32:597-603.
40. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007, 2:141-151.
41. Joniec I., Ciesielska A., Kurkowska-Jastrzebska I., Przybylkowski A., Czlonkowska A., Czlonkowski A. Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research 2009, 1261:7-19.
42. Kim J.H., Yenari M.A., Giffard R.G., Cho S.W., Park K.A., Lee J.E. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Experimental Neurology 2004, 1:122-130.
43. Kucheryanu V.G., Kryzhanovskii G.N. Effect of glutamate and antagonists of N-methyl-d-aspartate receptors on experimental parkinsonian syndrome in rats. Bulletin of Experimental Biology and Medicine 2000, 130:629-632.
44. Leitch B., Shevtsova O., Reusch K., Bergin D.H., Liu P. Spatial learning-induced increase in agmatine levels at hippocampal CA1 synapses. Synapse 2011, 65:146-153.
45. Liu P., Chary S., Devaraj R., Jing Y., Darlington C.L., Smith P.F., et al. Effects of aging on agmatine levels in memory-associated brain structures. Hippocampus 2008, 9:853-856.
46. Matsumoto T., Suzuki O., Furuta T., Asai M., Kurokawa Y., Nimura Y., et al. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clinical Biochemistry 1985, 2:126-129.
47. Meissner W., Hill M.P., Tison F., Gross C.E., Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends in Pharmacological Sciences 2004, 25:249-253.
48. Meredith G.E., Totterdell S., Beales M., Meshul C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Experimental Neurology 2009, 1:334-340.
49. Moosavi M., Yadollahi Khales G., Abbasi L., Zarifkar A., Rastegar K. Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. Neuropharmacology 2012, 62:2018-2023.
50. Moreira E.L., Rial D., Aguiar A.S., Figueiredo C.P., Siqueira J.M., DalBó S., et al. Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. Journal of Neural Transmission 2010, 117:1337-1351.
51. Naoi M., Nomura Y., Ishiki R., Suzuki H., Nagatsu T. 4-(O-Benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkyl amines as new inhibitors of type B monoamine oxidase. Journal of Neurochemistry 1998, 50:243-247.
52. Ohashi S., Mori A., Kurihara N., Mitsumoto Y., Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neuroscience Letters 2006, 401:183-187.
53. Ookubo M., Yokoyama H., Kato H., Araki T. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice. Molecular and Cellular Endocrinology 2009, 2:62-68.
54. Paszcuk A.F., Gadotti V.M., Tibola D., Quintão N.L., Rodrigues A.L., Calixto J.B., et al. Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. Brain Research 2007, 1159:124-133.
55. Piermartiri T.C., Figueiredo C.P., Rial D., Duarte F.S., Bezerra S.C., Mancini G., et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Experimental Neurology 2010, 226:274-284.
56. Prediger R.D., Aguiar A.S., Matheus F.C., Walz R., Antoury L., Raisman-Vozari R., et al. Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotoxicity Research 2012, 21:90-116.
57. Prediger R.D., Aguiar A.S., Moreira E.L., Matheus F.C., Castro A.A., Walz R., et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Current Pharmaceutical Design 2011, 17:489-507.
58. Prediger R.D., Aguiar A.S., Rojas-Mayorquin A.E., Figueiredo C.P., Matheus F.C., Ginestet L., et al. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotoxicity Research 2010, 2:114-129.
59. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental Neurology 2006, 2:391-403.
60. Raasch W., Jungbluth B., Schäfer U., Häuser W., Dominiak P. Norepinephrine release is reduced by I(1)-receptors in addition to alpha(2)-adrenoceptors. Annals of the New York Academy of Sciences 2003, 1009:270-273.
61. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain. Trends in Pharmacological Sciences 2000, 5:187-193.
62. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., De Andrade M., et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 3:200-209.
63. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Annals of Neurology 1998, 44:S175-S188.
64. Santos A.R., Gadotti V.M., Oliveira G.L., Tibola D., Paszcuk A.F., Neto A., et al. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 2005, 48:1021-1034.
65. Schneider J.S., Tinker J.P., Van Velson M., Giardiniere M. Effects of the partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Research 2000, 31:190-194.
66. Schwarzbold M.L., Rial D., De Bem T., Machado D.G., Cunha M.P., dos Santos A.A., et al. Effects of traumatic brain injury of different severity on emotional, cognitive and oxidative stress-related parameters in mice. Journal of Neurotrauma 2010, 10:1883-1893.
67. Seo S., Liu P., Leitch B. Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience 2011, 192:28-36.
68. Unzeta M., Baron S., Perez V., Ambrosio S., Mahy N. Sex-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine treatment may be related to differences in monoamine oxidase B. Neuroscience Letters 1994, 176:235-238.
69. Wang A.L., Liou Y.M., Pawlak C.R., Ho Y.J. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behavioural Brain Research 2010, 208:38-46.
70. Yang X.C., Reis D.J. Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. Journal of Pharmacology and Experimental Therapeutics 1999, 288:544-549.
71. Zarifkar A., Choopani S., Ghasemi R., Naghdi N., Maghsoudi A.H., Maghsoudi N., et al. Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis. European Journal of Pharmacology 2010, 634:84-88.
72. Zhu M.Y., Piletz J.E., Halaris A., Regunathan S. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cellular and Molecular Neurobiology 2003, 23:865-872.
73. Zomkowski A.D., Hammes L., Lin J., Calixto J.B., Santos A.R., Rodrigues A.L. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002, 13:387-391.
74. Zomkowski A.D., Santos A.R., Rodrigues A.L. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neuroscience Letters 2005, 381:279-283.